This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Philips (PHG) Gains Despite Recall of SENSE XL Torso Coils
by Zacks Equity Research
Philips (PHG) issues an urgent recall of SENSE XL Torso coils (1.5T and 3.0T) due to heating risks during MRI scans.
Philips' (PHG) Diagnosis & Treatment Segment Drives Growth
by Zacks Equity Research
Philips (PHG) boosts Diagnosis & Treatment on the back of Precision Diagnosis and Image-Guided Therapy businesses and an expanding partner base.
Philips (PHG) Aids Image-Guided Treatment With New Stent System
by Zacks Equity Research
Philips (PHG) boosts its Image-Guided Therapy portfolio with the Duo Venous Stent System, strengthening its Diagnosis & Treatment segment.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Philips (PHG) Boosts Precision Diagnosis With AI Platform
by Zacks Equity Research
Philips (PHG) boosts its Precision Diagnosis portfolio with an AI-powered ultrasound platform, strengthening its Diagnosis & Treatment segment.
Philips (PHG) Boosts Medical Imaging Footprint With New Move
by Zacks Equity Research
Philips (PHG) expands its international footprint with the wide availability of VeriSight Pro 3D to several Hong Kong hospitals, strengthening its Diagnosis & Treatment segment.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Royal Philips (PHG) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Philips (PHG) Strengthens Patient Monitoring Services in Spain
by Zacks Equity Research
Philips (PHG) announces the wide availability of its ambulatory cardiac monitoring service in Spain, boosting its patient monitoring solutions portfolio.
Philips' (PHG) Reports Positive AI-Powered Cardiac Study Data
by Zacks Equity Research
Philips' (PHG) AI-powered cardiac monitoring solutions demonstrate significantly lower re-admissions and a higher rate of survival in the retrospective study evaluating it in stroke patients.
Philips' (PHG) Gets FDA Recall for Trilogy Ventilator Glitch
by Zacks Equity Research
Philips' (PHG) software update for Trilogy Evo ventilators is set to mitigate a possible power malfunction and gets FDA Class I recall identification, as it may cause serious harm.
PHG vs. HAE: Which Stock Is the Better Value Option?
by Zacks Equity Research
PHG vs. HAE: Which Stock Is the Better Value Option?
Are Investors Undervaluing Koninklijke Philips (PHG) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Royal Philips (PHG) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Philips (PHG) Q1 Earnings Beat Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Philips' (PHG) first-quarter results benefit from strong momentum across the Diagnosis & Treatment and Personal Health businesses. However, softness in the Connected Care business is a concern.
Philips (PHG) Receives FDA Warning Letter Regarding CT Systems
by Zacks Equity Research
Philips (PHG) receives a warning letter from the FDA in respect of a manufacturing plant in China regarding faults in the manufacturing of CT systems.
Philips' (PHG) Zenition 30 to Boost Image-Guided Surgeries
by Zacks Equity Research
Philips (PHG) announces the FDA clearance for its Zenition 30 mobile C-arm, which is intended to aid in image-guided procedures at a relatively affordable cost.
Philips (PHG) Agrees to a Consent Decree With DOJ and FDA
by Zacks Equity Research
Philips (PHG) announces a consent decree with the U.S. government and FDA over Respironics' business recalls.
Philips (PHG) Boosts Patient Monitoring With smartQare Deal
by Zacks Equity Research
Philips (PHG) partners with smartQare to integrate the latter's viQtor solution, boosting its patient monitoring solutions portfolio.
Philips (PHG) Expands Sonicare Portfolio With Latest Launch
by Zacks Equity Research
Philips (PHG) adds Philips One for Kids toothbrush into its Sonicare family, boosting its Personal Health business.
Philips (PHG), AWS Unite to Scale Digital Pathology Solutions
by Zacks Equity Research
Philips (PHG) collaborates with Amazon Web Services to boost cloud-based pathology solutions. It will enable pathology laboratories to use digital processes to improve analytical capabilities.
Philips (PHG) Aids Personal Health Business With New Campaign
by Zacks Equity Research
Philips (PHG) launches #ShareTheCare brand positioning campaign for Philips Avent, bolstering the Personal Health segment.
Philips (PHG), SyntheticMR Unite to Aid Brain Diagnosing Space
by Zacks Equity Research
Philips (PHG) and SyntheticMR collaborate to launch of Smart Quant Neuro 3D, which is likely to boost the brain diagnosing field by providing automatic and precise 3D segmentation of brain tissues.
Philips' (PHG) CT 5300 to Boost Diagnostic Capabilities
by Zacks Equity Research
Philips (PHG) announces its latest innovation, Philips CT 5300, which leverages the power of AI at every stage in CT scanner operation to enhance productivity and diagnostic capabilities.
Philips (PHG) Aids Diagnostic Imaging With Philips CT 5300
by Zacks Equity Research
Philips (PHG) introduces AI-enabled Philips CT 5300 X-ray CT system, expanding its diagnostic imaging portfolio.